COSCIENS Historical Balance Sheet
| CSCI Stock | 3.22 0.02 0.63% |
Trend analysis of COSCIENS Biopharma balance sheet accounts such as Short Long Term Debt of 85.5 K, Total Assets of 35.6 M or Total Current Liabilities of 1.7 M provides information on COSCIENS Biopharma's total assets, liabilities, and equity, which is the actual value of COSCIENS Biopharma to its prevalent stockholders. By breaking down trends over time using COSCIENS Biopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
COSCIENS Biopharma Inventory |
|
COSCIENS |
About COSCIENS Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of COSCIENS Biopharma at a specified time, usually calculated after every quarter, six months, or one year. COSCIENS Biopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of COSCIENS Biopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which COSCIENS currently owns. An asset can also be divided into two categories, current and non-current.
COSCIENS Biopharma Balance Sheet Chart
Add Fundamental
Long Term Debt
Long-term debt is a debt that COSCIENS Biopharma has held for over one year. Long-term debt appears on COSCIENS Biopharma balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on COSCIENS Biopharma balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Short Long Term Debt
The total of a company's short-term and long-term borrowings.Total Assets
Total assets refers to the total amount of COSCIENS Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in COSCIENS Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on COSCIENS Biopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of COSCIENS Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from COSCIENS Biopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into COSCIENS Biopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.As of now, COSCIENS Biopharma's Total Liabilities is decreasing as compared to previous years. The COSCIENS Biopharma's current Intangible Assets is estimated to increase to about 11.3 K, while Total Assets are projected to decrease to under 35.6 M.
| 2010 | 2024 | 2025 (projected) | Short and Long Term Debt | 141.5K | 65.0K | 85.5K | Long Term Debt | 47.1K | 42.4K | 37.7K |
COSCIENS Biopharma balance sheet Correlations
Click cells to compare fundamentals
COSCIENS Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Currently Active Assets on Macroaxis
When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 3.759 | Quarterly Revenue Growth 0.041 | Return On Assets (0.23) | Return On Equity |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.